Help paying · Medicare negotiated price · pharmacy cost · cycle 2026
Farxiga (dapagliflozin): where help paying exists, what Medicare negotiated and what pharmacies pay
A program that covered this drug has changed its terms; the details and the source are below. Medicare's negotiated price for a 30-day supply is $179 (in force since January 1, 2026). A scheduled change takes it to $183 on January 1, 2027. Per unit, the negotiated price is 50% of NADAC, the pharmacy acquisition benchmark. 1 non-manufacturing label change is dated in the last 12 months in the FDA's file. ClinicalTrials.gov lists 98 recruiting trials that name dapagliflozin.
One package, side by side
Price per unit for one package of Farxiga. The negotiated price applies to Medicare Part D; NADAC is a survey of what retail pharmacies pay to buy the drug.
Swipe to read across
Every package we can price
Per-unit prices (per each unit, as the files state). "Scheduled" is a price the CMS file already dates for the future.
| NDC | Product | Unit | Negotiated now | Scheduled | NADAC | Share |
|---|---|---|---|---|---|---|
| 00003-1427-11 | Farxiga | n/a | $6.05 | $6.22 | n/a | no NADAC price |
| 00003-1427-12 | (name not listed) | n/a | $6.05 | $6.22 | n/a | no NADAC price |
| 00003-1427-13 | (name not listed) | n/a | $6.05 | $6.22 | n/a | no NADAC price |
| 00003-1427-14 | (name not listed) | n/a | $6.05 | $6.22 | n/a | no NADAC price |
| 00003-1427-91 | (name not listed) | n/a | $6.05 | $6.22 | n/a | no NADAC price |
| 00003-1428-11 | Farxiga | n/a | $6.05 | $6.22 | n/a | no NADAC price |
| 00003-1428-12 | (name not listed) | n/a | $6.05 | $6.22 | n/a | no NADAC price |
| 00003-1428-13 | (name not listed) | n/a | $6.05 | $6.22 | n/a | no NADAC price |
| 00003-1428-14 | (name not listed) | n/a | $6.05 | $6.22 | n/a | no NADAC price |
| 00003-1428-91 | (name not listed) | n/a | $6.05 | $6.22 | n/a | no NADAC price |
| 00310-6205-30 | Farxiga 5mg 30 CT Bottle | EA | $6.05 | $6.22 | $12.07 | 50% |
| 00310-6205-90 | FARXIGA TAB 5MG BT 1X90 EA US | EA | $6.05 | $6.22 | $12.07 | 50% |
| 00310-6210-30 | Farxiga 10MG 30CT | EA | $6.05 | $6.22 | $12.08 | 50% |
| 00310-6210-39 | FARXIGA TAB 10MG HUD BL 3X10 EA US | EA | $6.05 | $6.22 | $12.08 | 50% |
| 00310-6210-90 | FARXIGA TAB 10MG BT 1X90 EA US | EA | $6.05 | $6.22 | $12.08 | 50% |
| 66993-0456-30 | Dapagliflozin Tablets 5 mg, 30 | EA | $6.05 | $6.22 | $0.163 | generic, not compared |
| 66993-0457-30 | Dapagliflozin Tablets 10 mg, 30 | EA | $6.05 | $6.22 | $0.184 | generic, not compared |
When could a generic arrive
Each date below is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
| Application | Product | Latest listed patent expiry | Latest listed exclusivity expiry | Latest of the two | Set by |
|---|---|---|---|---|---|
| NDA202293 | Dapagliflozin Tablets 10 Mg, 30, Dapagliflozin Tablets 5 Mg, 30, Farxiga 10mg 30ct, Farxiga 5mg 30 Ct Bottle and 3 more | October 1, 2041 | December 12, 2027 | October 1, 2041 | patent 12213988 with its pediatric extension; 64 dated entries listed |
Source: FDA Orange Book data files, edition September 2026, read November 7, 2026; patent listings are as submitted by applicants and not verified by FDA. FDA data file.
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Farxiga of $5.29 billion in 2024, across 5,634,650 claims and 1,269,216 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $5.29 billion | 5,634,650 | 1,269,216 | $939 |
| 2023 | $4.34 billion | 4,298,827 | 993,909 | $1,010 |
| 2022 | $2.58 billion | 2,665,029 | 638,800 | $970 |
| 2021 | $1.42 billion | 1,540,905 | 385,693 | $923 |
| 2020 | $736.79 million | 858,348 | 193,920 | $858 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2025, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 10 states with the largest reimbursement are shown of 36 with data. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| CA | 8,485 | $11,584,538 | Fee-for-service only |
| NY | 11,582 | $10,250,980 | Fee-for-service only |
| TX | 16,007 | $8,430,881 | Fee-for-service only |
| OH | 3,732 | $2,855,830 | All record types |
| PA | 2,207 | $1,718,976 | Fee-for-service only |
| KY | 2,069 | $1,613,664 | Fee-for-service only |
| AZ | 1,303 | $1,277,321 | Fee-for-service only |
| IL | 1,396 | $1,244,144 | Fee-for-service only |
| WV | 1,742 | $1,064,473 | All record types |
| IN | 1,392 | $940,807 | Fee-for-service only |
Where the publisher suppresses small managed-care cells, a state's figure covers fee-for-service claims only and understates use (27 state and package figures are marked that way here). A state missing from the table means its figures were suppressed or not reported, not zero use. 177 older-year figures are held and left out of the table.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2025, modified 2026-07-13T15:28:32Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Where help paying exists
No program in our finder currently lists this drug as open to new patients.
Label changes
FDA actions on the applications behind Farxiga dated since November 11, 2025, leaving out manufacturing (CMC) changes. 1 change in the window.
| Date | Class | Application | Submissions | FDA documents |
|---|---|---|---|---|
| June 3, 2026 | Labeling | NDA202293 | 35 | Label (PDF) posted June 9, 2026FDA letter posted June 5, 2026 |
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Clinical trials recruiting
ClinicalTrials.gov lists 98 interventional trials that name dapagliflozin and are recruiting, and 45 more not yet recruiting. By phase: Phase 4: 32, Phase 3: 28, Phase 2: 18, Not applicable: 10, PHASE2/PHASE3: 4, Phase 1: 4, Early phase 1: 1, PHASE1/PHASE2: 1. The 10 most recently updated are below. A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
| Trial | Title and conditions | Phase | Lead sponsor | Last updated | Countries |
|---|---|---|---|---|---|
| NCT07323524 | Dapagliflozin in Active Lupus NephritisLupus Nephritis (LN) | Phase 4 | Brigham and Women's Hospital | November 6, 2026 | United States |
| NCT06742723 | A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureChronic Kidney Disease and Hypertension | Phase 3 | AstraZeneca | November 6, 2026 | United States, Argentina, Australia and 7 more |
| NCT07235280 | Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung AdenocarcinomaLung Adenocarcinoma; Stage IA1 Lung Cancer American Joint Committee on Cancer (AJCC) v8; Stage IA2 Lung Cancer AJCC v8 | Early phase 1 | Jonsson Comprehensive Cancer Center | November 5, 2026 | United States |
| NCT07351643 | CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM SyndromeACS (Acute Coronary Syndrome); SGLT2 Inhibitors | Phase 4 | Shenyang Northern Hospital | October 30, 2026 | China |
| NCT07662109 | A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusType 2 Diabetes Mellitus | Phase 3 | AstraZeneca | October 30, 2026 | United States, Argentina, Brazil and 7 more |
| NCT07310433 | Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate CancerProstate Cancer; Metastatic Prostate Cancer | Phase 2 | Yung NA | October 28, 2026 | China |
| NCT06281899 | Effect of Low Protein Diet on Top of Dapagliflozin on Chronic Kidney Disease in Patients With Type 2 Diabetes MellitusChronic Kidney Diseases; Type 2 Diabetes Mellitus | Phase 4 | Anemia Working Group Romania | October 28, 2026 | Romania |
| NCT06668389 | Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status TrialCongenital Heart Disease; Repaired Tetralogy of Fallot (rTOF); Pulmonary Regurgitation | Phase 4 | The University of Hong Kong | October 28, 2026 | Hong Kong |
| NCT07569640 | HFrEF Polypill in Sri Lanka RCTHeart Failure With Reduced Ejection Fraction | Phase 3 | Washington University School of Medicine | October 22, 2026 | Sri Lanka |
| NCT06677060 | Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinHeart Failure | Phase 3 | AstraZeneca | October 21, 2026 | United States, Argentina, Australia and 7 more |
Source: ClinicalTrials.gov, registry data processed November 6, 2026, summarized and trimmed by OmniRx. Search on ClinicalTrials.gov.
Questions
What is the Medicare negotiated price of Farxiga?
For a 30-day supply the price CMS published is $179, in force since January 1, 2026. The CMS file also schedules $183 from January 1, 2027. This is a price CMS agreed with the manufacturer for Medicare Part D, not what a person pays at the counter.
How does the negotiated price compare with what pharmacies pay?
Across the 5 packages where both CMS files give a price per unit, the median negotiated price is 50% of NADAC, the pharmacy acquisition benchmark (NADAC as of November 4, 2026). NADAC is a survey average, not a quote.
Is there help paying for Farxiga?
No program in our finder currently lists it as open to new patients. AZ&Me no longer accepts new patients for FARXIGA and XIGDUO XR from 2026-05-01; actively enrolled patients continue until 2026-12-31; the notice says generic equivalents became available beginning in April 2026 and that the products will be removed from the program by the end of 2026; communications went to enrolled patients and providers in April 2026
When could a generic version of Farxiga arrive?
For Farxiga, the FDA's Orange Book (edition September 2026) lists these latest patent or exclusivity expiry dates by application: NDA202293, October 1, 2041. Each date is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
Can I join a clinical trial for Farxiga?
ClinicalTrials.gov lists 98 recruiting interventional trials that name dapagliflozin (registry data processed November 6, 2026). A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
Is there a generic version of Farxiga?
An authorized generic of Farxiga (marketed by Prasco Laboratories under the same FDA application, NDA202293, since January 3, 2024, per the FDA's NDC directory) has a pharmacy acquisition cost (NADAC, November 4, 2026) of $0.163 to $0.184 per unit. Medicare's negotiated price per unit in force is $6.05, about 32.8 to 37.1 times that. These are two different kinds of figure: the negotiated price is a Medicare Part D price and NADAC is a survey of what pharmacies pay, neither is what a person pays at the counter.
How much does Medicare Part D spend on Farxiga?
CMS's Medicare Part D spending dataset reports gross spending on Farxiga of $5.29 billion in 2024, across 5,634,650 claims and 1,269,216 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns price, generic-entry upper bound, label history, recalls, trials, assistance, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/farxiga.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. CMS Medicare Drug Price Negotiation Program data file (read November 6, 2026; the CMS page states no licence or restriction); CMS NADAC from data.medicaid.gov under the labels in the OmniRx licence ledger; program details read from each program's own pages; CMS Medicare Part D spending by drug; FDA Drugs@FDA and Orange Book data files; ClinicalTrials.gov registry data. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.